Physician profile
Kevin D Sieck
NPI 1639190770
$693.07
in general payments reported to CMS, 2019-2025
14 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.82 · 2020: $135 · 2021: $246 · 2022: $99.16 · 2023: $30.00 · 2024: $13.39 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $168.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $198.01 | 2020-2022 | |
| Abbvie INC. | $162.96 | 2021-2025 | Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $107.64 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $68.80 | 2021-2025 | |
| Amarin Pharma, INC. | $30.28 | 2019-2020 | |
| Medtronic, INC. | $18.04 | 2025 | Abre |
| Novo Nordisk INC | $16.30 | 2019 | |
| Lilly USA, LLC | $14.95 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.18 | 2022 | |
| Merck Sharp & Dohme LLC | $13.57 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.40 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $12.43 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $11.54 | 2021 | |
| Astellas Pharma US INC | $10.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Sieck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.